197 related articles for article (PubMed ID: 8285144)
21. Is ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] unusually reactive for an imide?
Sisco JM; Stella VJ
Pharm Res; 1992 Aug; 9(8):1076-82. PubMed ID: 1409381
[TBL] [Abstract][Full Text] [Related]
22. In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
Sobol MM; Amiet RG; Green MD
Mol Pharmacol; 1992 Jan; 41(1):8-17. PubMed ID: 1732725
[TBL] [Abstract][Full Text] [Related]
23. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
25. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
Hasinoff BB; Tran KT
J Inorg Biochem; 1999; 77(3-4):257-9. PubMed ID: 10643663
[TBL] [Abstract][Full Text] [Related]
26. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
27. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
Gorbsky GJ
Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
[TBL] [Abstract][Full Text] [Related]
28. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
29. Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities.
Zima T; Tesar V; Richardson PJ; Mantle D; Preedy VR
Toxicol Appl Pharmacol; 2001 Mar; 171(3):135-40. PubMed ID: 11243912
[TBL] [Abstract][Full Text] [Related]
30. The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.
Schroeder PE; Patel D; Hasinoff BB
Drug Metab Dispos; 2008 Sep; 36(9):1780-5. PubMed ID: 18515330
[TBL] [Abstract][Full Text] [Related]
31. The pH dependent properties of metallotransferrins: a comparative study.
Messori L; Poggetto GD; Monnanni R; Hirose J
Biometals; 1997 Oct; 10(4):303-13. PubMed ID: 9353879
[TBL] [Abstract][Full Text] [Related]
32. Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ADR-529) on iron-catalyzed lipid peroxidation.
Ryan TP; Samokyszyn VM; Dellis S; Aust SD
Chem Res Toxicol; 1990; 3(4):384-90. PubMed ID: 1966787
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
[TBL] [Abstract][Full Text] [Related]
34. Iron uptake and transfer from ceruloplasmin to transferrin.
Eid C; Hémadi M; Ha-Duong NT; El Hage Chahine JM
Biochim Biophys Acta; 2014 Jun; 1840(6):1771-81. PubMed ID: 24418516
[TBL] [Abstract][Full Text] [Related]
35. An unexpected hydrolysis pH-rate profile, at pH values less than 7, of the labile imide, ICRF-187: (+)-1,2-bis-(3,5-dioxopiperazin-1-yl)propane.
Sisco JM; Stella VJ
Pharm Res; 1992 Sep; 9(9):1209-14. PubMed ID: 1409406
[TBL] [Abstract][Full Text] [Related]
36. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
38. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
39. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line.
Wadler S; Green MD; Muggia FM
Cancer Res; 1986 Mar; 46(3):1176-81. PubMed ID: 3080237
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis.
Burke TG; Lee TD; van Balgooy J; Doroshow JH
J Pharm Sci; 1991 Apr; 80(4):338-40. PubMed ID: 1907658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
